The efficacy of oxycodone for management of acute pain episodes in chronic neck pain patients

Ma, Ke; Jiang, Wei; Zhou, Qun; Du, Dongping

doi:10.1111/j.1742-1241.2007.01567.x

Cited by 30 publications

(25 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One report showed that short-term administration of 5 to 10 mg oxycodone was effective in the control of acute neck pain [17]. It was also reported that intravenous injection of 0.3 mg/kg morphine in patients with chronic whiplash injury decreased the pain by 50% or more [18].…”

Section: Early Opioid Treatmentmentioning

confidence: 99%

Guidelines for prescribing opioids for chronic non-cancer pain in Korea

et al. 2016

View full text Add to dashboard Cite

As the treatment of chronic non-cancer pain gradually increases, clinicians have more opportunities to encounter opioid prescription. However, guidelines for prescribing opioids for chronic non-cancer pain have never been published in Korea. The present guidelines were prepared by reviewing various research data. In cases in which the data were insufficient, recommendations were presented following discussion among experts affiliated with the Opioids Research Group in the Korean Pain Society. The present guidelines may need to be continuously revised and amended as more clinical evidence is acquired.

show abstract

Section: Early Opioid Treatmentmentioning

confidence: 99%

Guidelines for prescribing opioids for chronic non-cancer pain in Korea

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Oncologic resections of the head and neck are of particular interest, since postoperative pain suffers interference from movements of the neck and swallowing, which can exacerbate the pain and result in failure of the analgesics treatment. Controlled-release oxycodone may be an important drug option for the treatment of acute refractory and frequent episodes of chronic neck pain in patients with response failure to conservative non-opioid treatment 10 . The recent interest for oxycodone is based on its pharmacokinetic and pharmacodynamic properties, especially on the central nervous system.…”

Section: Discussion Discussion Discussion Discussion Discussionmentioning

confidence: 99%

Safety and tolerability of controlled-release oxycodone on postoperative pain in patients submitted to the oncologic head and neck surgery

Cavalcanti

Carvalho

Musauer

et al. 2014

Rev. Col. Bras. Cir.

View full text Add to dashboard Cite

Safety and tolerability of controlled-release oxycodone on Safety and tolerability of controlled-release oxycodone on Safety and tolerability of controlled-release oxycodone on Safety and tolerability of controlled-release oxycodone on Safety and tolerability of controlled-release oxycodone on postoperative pain in patients submitted to the oncologic head postoperative pain in patients submitted to the oncologic head postoperative pain in patients submitted to the oncologic head postoperative pain in patients submitted to the oncologic head postoperative pain in patients submitted to the oncologic head and neck surgery and neck surgery and neck surgery and neck surgery and neck surgery Segurança e tolerabilidade da oxicodona de liberação controlada em dores pós-Segurança e tolerabilidade da oxicodona de liberação controlada em dores pós-Segurança e tolerabilidade da oxicodona de liberação controlada em dores pós-Segurança e tolerabilidade da oxicodona de liberação controlada em dores pós-Segurança e tolerabilidade da oxicodona de liberação controlada em dores pós-operatórias em pacientes submetidos à operações oncológicas de cabeça e operatórias em pacientes submetidos à operações oncológicas de cabeça e operatórias em pacientes submetidos à operações oncológicas de cabeça e operatórias em pacientes submetidos à operações oncológicas de cabeça e operatórias em pacientes submetidos à operações oncológicas de cabeça e pescoço pescoço pescoço pescoço pescoço We conducted a prospective, observational and open study, with 83 patients with moderate to severe pain after head and neck oncological operations. All patients received general anesthesia with propofol, fentanyl and sevoflurane. Postoperatively, should they have moderate or severe pain, we began controlled-release oxycodone 20 mg 12/12 b.i.d on the first day and 10 mg b.i.d. on the second. We assessed the frequency and intensity of adverse effects, the intensity of postoperative pain by a verbal numeric scale and the use of rescue analgesia from 12 hours after administration of the drug and between 7 and 13 days after the last oxycodone dose. Results Results ResultsResults Results: The most common adverse events were nausea, vomiting, dizziness, pruritus, insomnia, constipation and urinary retention, most mild. No serious adverse events occurred. In less than 12 hours after the use of oxycodone, there was a significant decrease in the intensity of postoperative pain, which remained until the end of the study. The rescue medication was requested at a higher frequency when the opioid dose was reduced, or after its suspension. Conclusion Conclusion Conclusion Conclusion Conclusion: Controlled release oxycodone showed to be safe and well tolerated and caused a significant decrease in postoperative pain.

show abstract

“…In these conditions, central analgesics may be more appropriate, since they target the opioidergic system and the descending inhibitory pathways 10. The efficacy of opioids in neck pain and/or cervical radiculopathy has been poorly investigated to date,25–27 whereas there is evidence supporting their use in low-back pain (LBP) 28…”

Section: Introductionmentioning

confidence: 99%

Tapentadol extended release for the management of chronic neck pain

Billeci¹,

Coluzzi²

2017

JPR

View full text Add to dashboard Cite

BackgroundThe role of opioids in the management of chronic neck pain is still poorly investigated. No data are available on tapentadol extended release (ER). In this article, we present 54 patients with moderate-to-severe chronic neck pain treated with tapentadol ER.Patients and methodsPatients received tapentadol ER 100 mg/day; dosage was then adjusted according to clinical needs. The following parameters were recorded: pain; Douleur Neuropathique 4 score; Neck Disability Index score; range of motion; pain-associated sleep interference; quality of life (Short Form [36] Health Survey); Patient Global Impression of Change (PGIC); Clinician GIC; opioid-related adverse effects; and need for other analgesics.ResultsA total of 44 of 54 patients completed the 12-week observation. Tapentadol ER daily doses increased from 100 mg/day to a mean (standard deviation) dosage of 204.5 (102.8) mg/day at the final evaluation. Mean pain intensity at movement significantly decreased from baseline (8.1 [1.1]) to all time points (P<0.01). At baseline, 70% of patients presented a positive neuropathic component. This percentage dropped to 23% after 12 weeks. Tapentadol improved Neck Disability Index scores from 55.6 (18.6) at baseline to 19.7 (20.9) at the final evaluation (P<0.01). Tapentadol significantly improved neck range of motion in all three planes of motion, particularly in lateral flexion. Quality of life significantly improved in all Short Form (36) Health Survey subscales (P<0.01) and in both physical and mental status (P<0.01). Based on PGIC results, approximately 90% of patients rated their overall condition as much/very much improved. Tapentadol was well tolerated: no patients discontinued due to side effects. The use of other analgesics was reduced during the observed period.ConclusionOur results suggest that tapentadol ER, started at 100 mg/day, is effective and well tolerated in patients with moderate-to-severe chronic neck pain, including opioid-naïve subjects. Patients can expect a decrease in pain, an improvement in neck function, and a decrease in neuropathic symptoms.

show abstract

The efficacy of oxycodone for management of acute pain episodes in chronic neck pain patients

Abstract: Oxycondone controlled release could be an important optional drug for the management of refractory and frequent acute episodes of chronic neck pain in patients who failed to respond to non-opioid conservative treatment.

Cited by 30 publications

References 26 publications

Guidelines for prescribing opioids for chronic non-cancer pain in Korea

Guidelines for prescribing opioids for chronic non-cancer pain in Korea

Safety and tolerability of controlled-release oxycodone on postoperative pain in patients submitted to the oncologic head and neck surgery

Tapentadol extended release for the management of chronic neck pain

Contact Info

Product

Resources

About